AI Content

Showing 11245 articles
Business

Merck Navigates Mixed Q4 2025 with Oncology Strength Offsetting Vaccine Slump, Sets Cautious 2026 Outlook

Merck & Co. reported a 5% rise in Q4 2025 revenue to $16.4 billion, powered by its blockbuster cancer drug Keytruda and animal health division. However, a steep 35% drop in Gardasil sales, attributed to weakened demand in Asia, highlighted regional vulnerabilities. The pharmaceutical giant issued initial 2026 guidance projecting modest growth while absorbing a significant one-time charge from its recent Cidara Therapeutics acquisition.

Business

Invesco's 50% Surge: A Valuation Reality Check for the Asset Manager

Shares of Invesco Ltd. (IVZ) have delivered a stellar 50% return over the past year, dramatically outpacing its longer-term performance. This rally prompts a critical question: has the stock run too far, too fast? A deep dive into key valuation metrics reveals a complex and potentially overextended picture.